WallStreetZenWallStreetZen

NASDAQ: KZIA
Kazia Therapeutics Ltd Stock

$0.29+0.01 (+3.57%)
Updated May 16, 2024
KZIA Price
$0.29
Fair Value Price
$0.12
Market Cap
$7.75M
52 Week Low
$0.19
52 Week High
$1.34
P/E
-0.8x
P/B
2.24x
P/S
640.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$15.13k
Earnings
-$10.68M
Gross Margin
100%
Operating Margin
-69,438.83%
Profit Margin
-68,256.8%
Debt to Equity
3.63
Operating Cash Flow
-$9M
Beta
0.53
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

KZIA Overview

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KZIA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KZIA ($0.29) is overvalued by 135.62% relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KZIA ($0.29) is not significantly undervalued (135.62%) relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KZIA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KZIA due diligence checks available for Premium users.

Be the first to know about important KZIA news, forecast changes, insider trades & much more!

KZIA News

Valuation

KZIA fair value

Fair Value of KZIA stock based on Discounted Cash Flow (DCF)
Price
$0.29
Fair Value
$0.12
Overvalued by
132.42%
KZIA ($0.29) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KZIA ($0.29) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KZIA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KZIA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.8x
Industry
8.43x
Market
31.03x

KZIA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.24x
Industry
6.06x
KZIA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KZIA's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
KZIA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KZIA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$16.6M
Liabilities
$13.0M
Debt to equity
3.63
KZIA's short-term liabilities ($7.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KZIA's short-term assets ($5.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KZIA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KZIA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
KZIA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KZIA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
KZIA$7.75M+5.76%-0.80x2.24x
NCNA$7.76M-2.91%-0.22x0.43x
CYCN$7.72M-1.04%-71.25x0.78x
KTRA$8.02M+10.69%-0.04x1.35x
TRVN$7.46M-3.10%-0.15x-0.51x

Kazia Therapeutics Stock FAQ

What is Kazia Therapeutics's quote symbol?

(NASDAQ: KZIA) Kazia Therapeutics trades on the NASDAQ under the ticker symbol KZIA. Kazia Therapeutics stock quotes can also be displayed as NASDAQ: KZIA.

If you're new to stock investing, here's how to buy Kazia Therapeutics stock.

What is the 52 week high and low for Kazia Therapeutics (NASDAQ: KZIA)?

(NASDAQ: KZIA) Kazia Therapeutics's 52-week high was $1.34, and its 52-week low was $0.19. It is currently -78.06% from its 52-week high and 57.22% from its 52-week low.

How much is Kazia Therapeutics stock worth today?

(NASDAQ: KZIA) Kazia Therapeutics currently has 263,615,444 outstanding shares. With Kazia Therapeutics stock trading at $0.29 per share, the total value of Kazia Therapeutics stock (market capitalization) is $7.75M.

Kazia Therapeutics stock was originally listed at a price of $160.00 in Jan 6, 1999. If you had invested in Kazia Therapeutics stock at $160.00, your return over the last 25 years would have been -99.82%, for an annualized return of -22.27% (not including any dividends or dividend reinvestments).

How much is Kazia Therapeutics's stock price per share?

(NASDAQ: KZIA) Kazia Therapeutics stock price per share is $0.29 today (as of May 16, 2024).

What is Kazia Therapeutics's Market Cap?

(NASDAQ: KZIA) Kazia Therapeutics's market cap is $7.75M, as of May 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Kazia Therapeutics's market cap is calculated by multiplying KZIA's current stock price of $0.29 by KZIA's total outstanding shares of 263,615,444.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.